A Phase 3 interventional study of NVA237 and Tiotropium in Chronic Obstructive Pulmonary Disease, sponsored by Novartis Pharmaceuticals. Completed at 40 sites in Japan. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2013-01-18.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 34th largest by enrollment, is one of 5 that started in 2010, is one of 33 in phase 3, and was the 11th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Germany, United Kingdom
Ages 40–80
AstraZeneca · Sites in United States, Argentina, Australia and 34 more countries
Ages 40–80
By country, each count listing its studies:
Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 21 · Phase 3 33 · Phase 4 11
First in 2005; this study’s year is marked. 5 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 211 is above the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 152 across the 73 interventional studies. Of the 67 that completed or were terminated, 49 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
67 of 73 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
117 studies in Pulmonary Disease, Chronic Obstructive by Novartis: none open now, none under way, none of them phase 3. Of 110 finished, 94 (85%) have results posted.
Among the 117 studies in Pulmonary Disease, Chronic Obstructive by Novartis, this one is the 58th largest by enrollment of the 116 interventional ones that give a count, is one of 11 that started in 2010, is one of 59 in phase 3, and was the 45th registered.
Novartis’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2003.
1 of the studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 117 in Pulmonary Disease, Chronic Obstructive:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a 52-week, multi-center, randomized, open label, parallel group study to assess the long term safety and tolerability of once-daily NVA237, using tiotropium as an active control, in Japanese patients with moderate to severe chronic obstructive pulmonary disease (COPD) .
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
50µg once daily
Drug: NVA237
18µg once daily
Drug: Tiotropium
50µg capsules for inhalation, delivered via a single dose dry powder inhaler (Concept 1®)
18µg capsules for inhalation, delivered via HandiHaler®
Number of Participants With Adverse Events, Serious Adverse Events or Death
Adverse events are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal lab finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgments of the investigators represent significant hazards.
Time frame: 52 weeks
Change in Pre-dose FEV1 From Baseline
Pre-dose FEV1 is defined as the average of the measurements at 45 and 15 minutes pre-dose.
Time frame: Weeks 12, 24, 36 and 52
Change in Pre-dose FVC From Baseline
Pre-dose FVC is defined as the average of the measurements at 45 and 15 minutes pre-dose.
Time frame: Weeks 12, 24, 36 and 52
Time From Randomization Until the Start of the First Moderate or Severe COPD Exacerbation
Moderate COPD exacerbations were defined as: worsening of 2 or more of the following major symptoms for at least 2 consecutive days - dyspnea, sputum volume and sputum purulence; OR a worsening of any 1 major symptom with any 1 of the following minor symptoms for at least 2 consecutive days - sore throat, colds, fever without other cause, increased cough or increased wheeze, requiring treatment with systemic glucocorticosteroids or antibiotics or both. Severe COPD exacerbations were defined as: conditions for Moderate COPD exacerbation and hospitalization was required. Participants who withdraw from the study and do not experience a moderate or severe exacerbation are censored at the date of withdrawal. Participants who complete the study and do not experience a moderate or severe exacerbation are censored at the completion visit date.
Time frame: 52 weeks
Number of Patients With Moderate or Severe COPD Exacerbations
Moderate COPD exacerbations were defined as: worsening of 2 or more of the following major symptoms for at least 2 consecutive days - dyspnea, sputum volume and sputum purulence; OR a worsening of any 1 major symptom with any 1 of the following minor symptoms for at least 2 consecutive days - sore throat, colds, fever without other cause, increased cough or increased wheeze, requiring treatment with systemic glucocorticosteroids or antibiotics or both. Severe COPD exacerbations were defined as: conditions for Moderate COPD exacerbation and hospitalization was required.
Time frame: 52 weeks
Change in St. George Respiratory Questionnaire From Baseline
SGRQ is a health related quality of life questionnaire consisting of 51 items in three components: symptoms, activity, and impacts. The lowest possible value is zero and the highest 100. Higher values correspond to greater impairment in quality of life.
Time frame: Weeks 12, 24, 36, 52
Change From Baseline in Mean Daily Number of Puffs of Rescue Medication Over the Whole Treatment Period
Patients recorded rescue medication use in a paper patient diary. If a patient required the use of salbutamol as rescue medication due to an increase in COPD symptoms, the number of inhalations (puffs) taken was recorded in the patient diary.
Time frame: 52 weeks
Number of Patients With Newly Occurring or Worsening Clinically Notable Hematology Values at Any Timepoint Over the Whole Treatment Period
Clinically notable hematology values were: hemoglobin - male \<11.5g/dL, female \<9.5 g/dL; hematocrit - male \<37%, female \<32%; white cell count - \<2800µL or \>16000µL; platelets - \<7.5 10\*4/µL or \>70.0 10\*4/µL
Time frame: 52 weeks
Number of Patients With Newly Occurring or Worsening Clinically Notable Biochemistry Values at Any Timepoint Over the Whole Treatment Period
Clinically notable biochemistry values were: total protein - \<4.0 g/dL or \>9.5 g/dL; albumin \<2.5 g/dL; bilirubin (total) \>1.9 mg/dL; BUN \>27 mg/dL; creatinine \>1.99 mg/dL; AST \>3 x ULN U/L; ALT \>3 x ULN U/L; ALP \>3 x ULN U/L; y-GTP \>3 x ULN U/L; sodium \<125 mEq/L or \>160 mEq/L; potassium \<3.0 mEq/L or \>6.0 mEq/L; glucose \<51.0 mg/dL or \>180.0 mg/dL
Time frame: 52 weeks
Number of Patients With Newly Occurring or Worsening Clinically Notable Vital Signs Values at Any Timepoint Over the Whole Treatment Period
Clinically notable vital sign values were: pulse rate - low, \<40 bpm or \<=50 bpm and decrease from baseline \>=15bpm; pulse rate high, \>130 bpm or \>=120bpm and increase from baseline \>=15 bpm. Systolic blood pressure - low, \<75 mmHg or \<=90 mmHg and decrease from baseline \>=20 mmHg; high, \>200 mmHg or \>=180 mmHg and increase from baseline \>=20 mmHg. Diastolic blood pressure - low, \<40 mmHg or \<=50 mmHg and decrease from baseline \>=15 mmHg; high, \>115 mmHg or \>=105 mmHg and increase from baseline \>=15 mmHg.
Time frame: 52 weeks
Number of Patients With Notable Change From Baseline in Fridericia's QTc Values at Any Timepoint Over the Whole Treatment Period
Clinically notable change from baseline was and increase from baseline of 30 or greater milliseconds (ms).
Time frame: 52 weeks
| Milestone | NVA237 | Tiotropium |
|---|---|---|
| Started | 123 | 40 |
| Completed | 104 | 33 |
| Not completed | 19 | 7 |
| Withdrew: Adverse event | 11 | 5 |
| Withdrew: Protocol deviation | 3 | 1 |
| Withdrew: Unsatisfactory therapeutic effect | 3 | 0 |
| Withdrew: Withdrawal by subject | 2 | 1 |
Adverse events are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal lab finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgments of the investigators represent significant hazards.
| participants | NVA237 | Tiotropium |
|---|---|---|
| Adverse events | 102 | 33 |
| Serious adverse events | 16 | 6 |
| Death | 0 | 0 |
Pre-dose FEV1 is defined as the average of the measurements at 45 and 15 minutes pre-dose.
| liters | NVA237 | Tiotropium |
|---|---|---|
| Week 12 | 0.101 ± 0.1455 | 0.173 ± 0.1976 |
| Week 24 | 0.094 ± 0.1614 | 0.144 ± 0.1435 |
| Week 36 (n = 106, 36) | 0.084 ± 0.1558 | 0.112 ± 0.2200 |
| Week 52 (n = 103, 33) | 0.068 ± 0.1829 | 0.127 ± 0.2566 |
Pre-dose FVC is defined as the average of the measurements at 45 and 15 minutes pre-dose.
| liters | NVA237 | Tiotropium |
|---|---|---|
| Week 12 | 0.221 ± 0.3057 | 0.220 ± 0.3029 |
| Week 24 | 0.218 ± 0.2798 | 0.179 ± 0.2285 |
| Week 36 (n = 106, 36) | 0.208 ± 0.3204 | 0.146 ± 0.2547 |
| Week 52 (n = 103, 33) | 0.195 ± 0.3739 | 0.126 ± 0.2889 |
Moderate COPD exacerbations were defined as: worsening of 2 or more of the following major symptoms for at least 2 consecutive days - dyspnea, sputum volume and sputum purulence; OR a worsening of any 1 major symptom with any 1 of the following minor symptoms for at least 2 consecutive days - sore throat, colds, fever without other cause, increased cough or increased wheeze, requiring treatment with systemic glucocorticosteroids or antibiotics or both. Severe COPD exacerbations were defined as: conditions for Moderate COPD exacerbation and hospitalization was required. Participants who withdraw from the study and do not experience a moderate or severe exacerbation are censored at the date of withdrawal. Participants who complete the study and do not experience a moderate or severe exacerbation are censored at the completion visit date.
| days | NVA237 | Tiotropium |
|---|---|---|
| Time From Randomization Until the Start of the First Moderate or Severe COPD Exacerbation | 362 (2 to 372) | 359 (4 to 368) |
Moderate COPD exacerbations were defined as: worsening of 2 or more of the following major symptoms for at least 2 consecutive days - dyspnea, sputum volume and sputum purulence; OR a worsening of any 1 major symptom with any 1 of the following minor symptoms for at least 2 consecutive days - sore throat, colds, fever without other cause, increased cough or increased wheeze, requiring treatment with systemic glucocorticosteroids or antibiotics or both. Severe COPD exacerbations were defined as: conditions for Moderate COPD exacerbation and hospitalization was required.
| participants | NVA237 | Tiotropium |
|---|---|---|
| 0 exacerbations | 99 | 31 |
| 1 exacerbation | 17 | 5 |
| 2 exacerbations | 5 | 3 |
| 3 exacerbations | 1 | 0 |
| > = 4 exacerbations | 1 | 1 |
SGRQ is a health related quality of life questionnaire consisting of 51 items in three components: symptoms, activity, and impacts. The lowest possible value is zero and the highest 100. Higher values correspond to greater impairment in quality of life.
| score on a scale | NVA237 | Tiotropium |
|---|---|---|
| Week 12 | -2.57 ± 8.506 | -2.31 ± 13.654 |
| Week 24 | -1.77 ± 9.466 | -3.24 ± 12.908 |
| Week 36 | -2.54 ± 9.614 | -0.93 ± 14.214 |
| Week 52 | -2.68 ± 10.505 | 0.36 ± 15.389 |
Patients recorded rescue medication use in a paper patient diary. If a patient required the use of salbutamol as rescue medication due to an increase in COPD symptoms, the number of inhalations (puffs) taken was recorded in the patient diary.
| change in puffs | NVA237 | Tiotropium |
|---|---|---|
| Change From Baseline in Mean Daily Number of Puffs of Rescue Medication Over the Whole Treatment Period | -0.16 ± 1.039 | -0.27 ± 0.859 |
Clinically notable hematology values were: hemoglobin - male \<11.5g/dL, female \<9.5 g/dL; hematocrit - male \<37%, female \<32%; white cell count - \<2800µL or \>16000µL; platelets - \<7.5 10\*4/µL or \>70.0 10\*4/µL
| participants | NVA237 | Tiotropium |
|---|---|---|
| Hemoglobin - male (n = 121, 38) | 3 | 2 |
| Hemoglobin - female (n = 121, 38) | 0 | 0 |
| Hematocrit - male (n = 121, 38) | 3 | 4 |
| Hematocrit - female (n = 121, 38) | 0 | 0 |
| White cell count - <2800/µL | 0 | 1 |
| White cell count - >16000/µL | 0 | 0 |
| Platelets - <7.5 10*4/µL | 1 | 0 |
| Platelets - >70.0 10*4/µL | 0 | 0 |
Clinically notable biochemistry values were: total protein - \<4.0 g/dL or \>9.5 g/dL; albumin \<2.5 g/dL; bilirubin (total) \>1.9 mg/dL; BUN \>27 mg/dL; creatinine \>1.99 mg/dL; AST \>3 x ULN U/L; ALT \>3 x ULN U/L; ALP \>3 x ULN U/L; y-GTP \>3 x ULN U/L; sodium \<125 mEq/L or \>160 mEq/L; potassium \<3.0 mEq/L or \>6.0 mEq/L; glucose \<51.0 mg/dL or \>180.0 mg/dL
| participants | NVA237 | Tiotropium |
|---|---|---|
| Total protein - <4.0 g/dL | 0 | 0 |
| Total protein - >9.5 g/dL | 0 | 0 |
| Albumin - <2.5 g/dL | 0 | 0 |
| Bilirubin (total) - >1.9 mg/dL | 2 | 0 |
| BUN - >27 mg/dL | 3 | 0 |
| Creatinine - >1.99 mg/dL | 0 | 0 |
| AST - >3 x ULN U/L | 1 | 0 |
| ALT - >3 x ULN U/L | 0 | 0 |
| ALP - >3 x ULN U/L | 0 | 1 |
| Y-GTP - >3 x ULN U/L | 5 | 4 |
| Sodium - <125 mEq/L | 0 | 0 |
| Sodium - >160 mEq/L | 0 | 0 |
| Potassium - <3.0 mEq/L | 1 | 0 |
| Potassium - >6.0 mEq/L | 0 | 0 |
| Glucose - <51.0 mg/dL | 0 | 0 |
| Glucose - >180.0 mg/dL | 11 | 3 |
Clinically notable vital sign values were: pulse rate - low, \<40 bpm or \<=50 bpm and decrease from baseline \>=15bpm; pulse rate high, \>130 bpm or \>=120bpm and increase from baseline \>=15 bpm. Systolic blood pressure - low, \<75 mmHg or \<=90 mmHg and decrease from baseline \>=20 mmHg; high, \>200 mmHg or \>=180 mmHg and increase from baseline \>=20 mmHg. Diastolic blood pressure - low, \<40 mmHg or \<=50 mmHg and decrease from baseline \>=15 mmHg; high, \>115 mmHg or \>=105 mmHg and increase from baseline \>=15 mmHg.
| participants | NVA237 | Tiotropium |
|---|---|---|
| Pulse rate - low | 0 | 1 |
| Pulse rate - high | 0 | 0 |
| Pulse rate - low or high | 0 | 1 |
| Systolic blood pressure - low | 0 | 0 |
| Systolic blood pressure - high | 1 | 0 |
| Systolic blood pressure - low or high | 1 | 0 |
| Diastolic blood pressure - low | 1 | 0 |
| Diastolic blood pressure - high | 2 | 0 |
| Diastolic blood pressure - low or high | 3 | 0 |
Clinically notable change from baseline was and increase from baseline of 30 or greater milliseconds (ms).
| participants | NVA237 | Tiotropium |
|---|---|---|
| Increase from baseline 30 to 60 ms | 6 | 1 |
| Increase from baseline >60 ms | 2 | 0 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| NVA237 | — | 16/123 (13%) | 83/123 (67.5%) |
| Tiotropium | — | 6/40 (15%) | 33/40 (82.5%) |
| Event | NVA237 | Tiotropium |
|---|---|---|
| PneumoniaInfections and infestations | 0/123 | 2/40 |
| Angina unstableCardiac disorders | 0/123 | 1/40 |
| Bile duct stoneHepatobiliary disorders | 0/123 | 1/40 |
| ContusionInjury, poisoning and procedural complications | 0/123 | 1/40 |
| Heat illnessInjury, poisoning and procedural complications | 0/123 | 1/40 |
| Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/123 | 1/40 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 2/123 | 0/40 |
| Cardiac failureCardiac disorders | 1/123 | 0/40 |
| CataractEye disorders | 1/123 | 0/40 |
| Macular holeEye disorders | 1/123 | 0/40 |
| Event | NVA237 | Tiotropium |
|---|---|---|
| NasopharyngitisInfections and infestations | 37/123 | 13/40 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 28/123 | 13/40 |
| BronchitisInfections and infestations | 6/123 | 5/40 |
| HypertensionVascular disorders | 7/123 | 5/40 |
| ConstipationGastrointestinal disorders | 6/123 | 3/40 |
| GastritisGastrointestinal disorders | 1/123 | 3/40 |
| Upper respiratory tract infectionInfections and infestations | 6/123 | 3/40 |
| VertigoEar and labyrinth disorders | 2/123 | 2/40 |
| Dry mouthGastrointestinal disorders | 2/123 | 2/40 |
| ToothacheGastrointestinal disorders | 1/123 | 2/40 |
| Age Continuous(years) | NVA237 | Tiotropium | Total |
|---|---|---|---|
| Mean | 68.4 ± 7.29 | 69.4 ± 7.48 | 68.7 ± 7.32 |
| Sex: Female, Male(Participants) | NVA237 | Tiotropium | Total |
|---|---|---|---|
| Female | 2 | 2 | 4 |
| Male | 121 | 38 | 159 |
The record gives a start of May 2010 and a primary completion of Nov 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2013, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Glycopyrrolate · Tiotropium
Pulmonary Disease, Chronic Obstructive →